Clinical Evaluator

Mold Protocol & Practitioner Evaluator

Recommended Clinical Direction Protocol Fit: 92%
Dr. Neil Nathan / Cell Danger Response Approach with Gentle Binders
Estimated Initial Testing
$850 - $1,400
Optimal First Action
Somatic Stabilization + ERMI / Safe Space
Primary Caution
Severe Herx Risk if starting with Cholestyramine
Critical Clinical Cautions for This Profile
  • High reactivity / Mast cell sensitivity detected: prioritize nervous system regulation before aggressive binding.
  • European practitioner availability is limited; verify virtual vs in-person consult requirements.
Classic CIRS Model

Ritchie Shoemaker, MD Protocol

Rigid, biomarker-driven 12-step hierarchy designed to identify systemic inflammation and eliminate biotoxins through prescription bile-acid sequestrants.

Core Presumption: Genetically susceptible HLA-DR types fail to produce antibodies against biotoxins, causing innate immune loop.
Key Diagnostics: Visual Contrast Sensitivity (VCS), TGF-β1, C4a, MMP-9, MSH, VIP, Leptin, MARCoNS nasal culture.
Primary Interventions: Cholestyramine (CSM) or Welchol; BEG nasal spray for MARCoNS; VIP nasal spray for restoration.
Patient Suitability: Robust patients who tolerate pharmaceutical binders; less optimal for severe MCAS/Lyme reactive cases.
European Feasibility: Challenging (CSM requires local prescription; specialized CIRS blood markers require dry ice export).
Cell Danger Response (CDR) Recommended for Profile

Neil Nathan, MD Model (Toxic)

Patient-tailored, ultra-gentle sequencing focused on nervous system downregulation, mast cell stabilization, and targeted natural binders.

Core Presumption: Chronic infection (Lyme, Bartonella) and mold freeze mitochondria in Naviaux Cell Danger Response. Healing cannot start in fight-or-flight.
Key Diagnostics: Provoked/unprovoked urine mycotoxins (RealTime/Mosaic), Organic Acids (OAT), clinical sensitivity profiling.
Primary Interventions: Limbic retraining (Primal Trust/DNRS), mast cell stabilizers (quercetin, ketotifen), micro-dosed gentle binders (charcoal, bentonite, chlorella, saccharomyces boulardii).
Patient Suitability: Ideal for complex Lyme overlap, severe chemical intolerance, and dysautonomia.
European Feasibility: High (binders available over-the-counter; limbic and mast cell tools readily self-managed).
Clinical Brief Copied to Clipboard!
Enjoy this tool? Build your own with Super